Dear Colleague,

TWO UPDATES TO GUIDANCE

- PERTUSSIS: OCCUPATIONAL VACCINATION OF HEALTHCARE WORKERS
- HEALTHCARE WORKERS (HCW) LIVING WITH A BLOOD BORNE VIRUS (BBV)

PERTUSSIS: OCCUPATIONAL VACCINATION OF HEALTHCARE WORKERS

PHE have now published updated guidance for pertussis vaccination of HCWs: [https://www.gov.uk/government/publications/pertussis-occupational-vaccination-of-healthcare-workers](https://www.gov.uk/government/publications/pertussis-occupational-vaccination-of-healthcare-workers) though the Green Book chapter 12 (Immunisation of healthcare and laboratory staff) and chapter 24 (Pertussis) will be updated to reflect these changes as soon as is practicable.

HEALTHCARE WORKERS (HCW) LIVING WITH A BLOOD BORNE VIRUS (BBV)

The UK Advisory Panel has updated its advice on management of HCWs living with hepatitis B and includes changes to recommendations regarding ‘lookback’ / patient notification exercises relating to HCWs diagnosed with a BBV. Further information is in Annex A, below.

Annex A – Further information on changes for healthcare workers living with a blood borne virus

1. Healthcare workers (HCWs) living with Hepatitis B (HBV)

   The guidance on restrictions of HCWs living with HBV to perform exposure-prone procedures (EPPs) is being updated. Previous guidance published in October 2017 restricted the practice of HCWs living with HBV if they were e-Antigen (HBeAg) positive and/or they had a pre-treatment viral load of >20,000 IU/mL (10^5 gEq/ml). These restrictions are now being removed provided HCWs meet the criteria for clearance and comply with monitoring by an Occupational Health service, as described in the updated guidance.

From the Chief Medical Officer
Dr Catherine Calderwood MA
MRCP FRCP(Edin)

For action
Chief Executives, NHS Boards; Medical Directors, NHS Boards; Nurse Directors, NHS Boards; Chairs, NHS Boards; Directors of Pharmacy, NHS Boards; Directors of Public Health, NHS Boards; Infectious Disease Consultants, NHS Boards; NHS Board Consultants in Public Health Medicine; Immunisation Co-ordinators;

For information
Directors of Finance, NHS Boards; Health Protection Scotland; Chief Executive, Health Scotland NHS 24; Consultant Paediatricians; Consultant Physicians; BBV Sexual Health Lead Clinicians; HIV Lead Clinicians; Sexual Health Lead Clinicians; NHS Board Executive Leads for Sexual Health; General Practitioners; Practice Nurses;

Further Enquiries
BBV - Emma Pugh
E-mail: emma.pugh@gov.scot

Pertussis – Sarah Dillon
E-mail: sarah.dillon@gov.scot

22 October 2019
published by the UK Advisory Panel for Healthcare Workers Infected with Blood-borne Viruses (UKAP). This change is due to the lower risk of virus transmission with new effective treatments which are now available for HBV.

In addition, these HCWs living with HBV who wish to perform EPPs need to be registered on a confidential national register, the UKAP-OHR (UK Advisory Panel for Healthcare Workers Infected with Blood-borne Viruses – Occupational Health Monitoring Register for BBV Infected HCWs). The UKAP-OHR will be managed by Public Health England (PHE). Further information about how to register HCWs onto the UKAP-OHR can be found here.

1. Changes to recommendations regarding ‘lookback’ / patient notification exercises

Previous guidance recommended a series of investigations following the diagnosis of a BBV (i.e. HIV, HBV and Hepatitis C (HCV)) in a HCW who had undertaken EPPs; these included i) lookback initiatives to identify procedures undertaken by the HCW, ii) the cross-matching of resultant records with databases holding records of people diagnosed with BBVs to determine if any procedures had led to a subsequent diagnosis of a BBV and, where appropriate, iii) patient notification exercises involving the provision of information and the offer of BBV screening to those patients deemed at risk.

A review by UKAP found that, in instances where an HCW was identified as BBV infected but there was no initial evidence of HCW to patient transmission, patient notification exercises never identified any such transmissions; furthermore, such investigations are resource-intensive and patient notification often causes anxiety among those contacted. As a result of this review, the criteria for undertaking a detailed public health investigation and patient notification have been revised and these will now only be undertaken in circumstances where it is known (or suspected) that a patient has acquired infection from a HCW or where there is concern about the practice of the HCW which could have led to increased risk of exposure.

The changes described above are important in ensuring that the management of HCWs living with BBVs is proportionate, reflects the changing treatment options now available and our understanding of the long-term aspects of living with these infections, and at the same time ensures that patient safety is not compromised.

The intention is that the removal of restrictions on EPP practice and the recommendation that patient notification / lookback exercises are only undertaken in exceptional
circumstances will reassure HCWs and mean that they feel confident to seek advice and testing for BBVs, if they are concerned about exposures either in the workplace or in other settings.

HCWs should be reminded of the very considerable benefits of identifying and then treating a BBV. Treatments for HBV (if required) and HIV are generally safe, easy to take and highly effective in suppressing virus. For HCV, a short course of treatment is safe, easy to take and, for almost everyone, curative.

Further information about the contents of this letter can be obtained here, or by contacting UKAP (Ukap@phe.gov.uk).

**Action**

Chief Executives of NHS Boards should ensure that these changes are brought to the attention of all relevant staff.

Yours sincerely,

*Catherine Calderwood*

Dr Catherine Calderwood

*Chief Medical Officer*